Articles tagged with Enzyme Inhibitors
Researchers at TTUHSC have identified novel targets for treating stroke, focusing on enhancing neurolysin activity. The study discovered small molecules that can selectively enhance the activity of neurolysin, which showed promise in reducing damage to the brain after a stroke.
Researchers at the University of Alabama at Birmingham have identified DOT1L as a potential therapeutic target for ovarian cancer. Inhibitors of the DOT1L enzyme showed promise in reducing tumor growth and improving survival rates by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
The article highlights available treatment alternatives for mild and serious COVID-19 cases, as well as vaccine options that can confer immunity to vaccinated individuals. Researchers conclude a combinatorial therapy should be designed with both immunizations and small compounds.
A randomized trial found that continuing common heart medications in COVID-19 patients did not negatively impact their health. The trial enrolled 659 patients and showed no significant difference in the number of days alive and out of hospital between those who continued and suspended their medications.
Researchers have developed first-in-class inhibitors of the NSD1 protein, a key enzyme linked to several types of cancer. The lead compound, BT5, showed promising activity in leukemia cells with the NUP98-NSD1 chromosomal translocation.
The researchers developed new synthesis methods for polyheterocyclic compounds containing triazolo and tetrazolo moieties. These compounds were found to act as inhibitors for the Tankyrase I enzyme, showing potential in cancer treatment
An observational study investigated the association between ACEI and ARB use and COVID-19 positivity. The study found a significant correlation between ACEI/ARB use and increased likelihood of testing positive for COVID-19. The authors suggest that future studies should explore potential mechanisms underlying this association.
A study examined the association between renin-angiotensin system inhibitors and COVID-19 severity, finding no significant link to increased risk of death or severe illness. However, some studies suggest that these medications may exacerbate respiratory symptoms in patients with underlying hypertension.
Researchers at the University of Pennsylvania School of Medicine have discovered a way to modify PARP inhibitor compounds to increase their effectiveness in killing cancer cells. By structurally modifying veliparib, a previously ineffective compound, they were able to boost its ability to trap and kill tumor cells.
University of Groningen researchers used nanopore technology to observe a single enzyme in four different folded states, which play an active role in the reaction mechanism. The study's findings have significant implications for enzyme engineering and the development of inhibitors.
A newly identified compound, C1, is a covalent gamma-secretase inhibitor that blocks the production of amyloids by inhibiting the enzyme's activity on the amyloid precursor protein. This approach avoids traditional enzyme inhibitors' severe side effects and shows promise for treating Alzheimer's disease.
A University at Buffalo-led research team is studying molecular interactions that enable enzymes to accelerate chemical reactions. The goal is to understand how enzymes perform their job, with a focus on enzyme activation and inhibition.
A study by JAMA Network found a potential association between ACE inhibitors and ARBs and an increased risk of suicide among individuals with hypertension, diabetes, and chronic kidney disease. The observational study analyzed data from over 200,000 patients to identify any possible links between these medications and suicidal behavior.
Researchers have discovered a potent KRAS inhibitor, BI-2852, that can target both active and inactive forms of the enzyme. The compound has shown promising results in lab assays, paving the way for the development of specific RAS inhibitors for cancer therapy.
Researchers discovered that overexpressing macrophage migration inhibitory factor (MIF) in mice with SOD1 mutations slows down disease progression and extends lifespan. MIF may play a potential therapeutic role in ALS treatment.
Researchers developed new chromenone-based derivatives with potent AChE and BChE inhibitory activity. These dual inhibitors may be effective in treating neurodegenerative disorders like Alzheimer's disease.
Scientists have discovered a new OGG1 inhibitor that decreases lung inflammation in mice, which could lead to better treatments for diseases like sepsis and autoimmune disorders. The inhibitor blocks the onset of inflammation associated with oxidative stress, offering a new mechanism for preventing inflammatory conditions.
The Konstanz research team developed a technique to measure enzyme inhibition in living cells, which allows for the discovery of inhibitors targeting quinolone biosynthesis. Inhibiting this process disrupts bacterial communication and prevents toxin production, blocking infectious properties.
Researchers identified M21 as a compound that inhibits virulence factors in S. aureus via ClpP inhibition, reducing bacteria and abscesses in infected mice with improved survival rates. The findings suggest a potential alternative to antibiotics for treating drug-resistant S. aureus infections.
Researchers have identified TLK2 enzyme as a key player in several diseases, including breast cancer and intellectual disability. The study suggests that inhibiting the enzyme may be an effective therapy approach.
Researchers investigated the association between angiotensin-converting enzyme (ACE) polymorphisms and cognitive change in late-onset Alzheimer's disease dementia. They found that ACE inhibitors slowed cognitive decline independently of blood pressure variations, particularly for APOE4- carriers with specific ACE genotypes. No function...
Researchers have made significant breakthroughs in understanding and combating antibiotic resistance, particularly through the development of β-lactamase inhibitors. These enzyme inhibitors have shown promise in reversing resistance to certain antibiotics, offering new hope in treating previously untreatable infections.
Researchers created a small molecule that inhibits the formation of biofilms on tooth surfaces, reducing dental caries in rats fed a caries-promoting diet. The inhibitor blocks a key virulence enzyme, making it unable to stick to tooth surfaces and produce lactic acid.
Researchers at King Abdullah University of Science & Technology have identified three traditional Saudi plants with potent anticancer substances, including topoisomerase inhibitors. The study suggests these compounds could be used to develop novel cancer treatments, but more research is needed before they can be tested in humans.
Researchers found that inhibiting intestinal protein NCoR1 breaks down bilirubin, eliminating signs of severe neonatal hyperbilirubinemia in mice. This discovery could lead to new therapeutic approaches for preventing or treating the condition.
Researchers at Florida Atlantic University have developed novel protein inhibitors of MMPs, which could potentially treat cancer and other diseases. The inhibitors were designed to be specific to certain MMP targets, addressing the issue of side effects seen with previous synthetic inhibitors.
Researchers at Beth Israel Deaconess Medical Center identified an enzyme called SHP-2 that significantly contributes to the development of lupus. Inhibiting this enzyme can diminish lupus symptoms and suggest a new therapeutic approach for the disease.
Researchers at Duke University have discovered the structure of MraY enzyme, revealing a hidden binding pocket that can be targeted by muraymycin. This breakthrough provides a platform for designing broad-spectrum antibiotics that could combat antibiotic-resistant infections and save millions of lives.
Researchers discovered slow-binding inhibitors (SBIs) with high selectivity, long target-residence times, and minimal side effects for treating Alzheimer's disease, myasthenia, and neuroprotection. SBIs also have toxicological importance, playing a role in mechanisms of resistance against irreversible agents.
Two unique enzymes, AIG1 and ADTRP, have been discovered that play a role in metabolism and inflammation, potentially targeting type 2 diabetes and inflammatory disorders. The enzymes are moderately inhibited by lipase inhibitors, suggesting they may be used to boost FAHFAs, which normalize glucose levels and reduce inflammation.
Researchers developed a molecule that can inhibit an enzyme linked with the onset of stroke, reducing brain damage by as much as 66 percent. The inhibitor, known as 6S, works by binding to cystathionine beta-synthase and reducing inflammation in stroke patients.
The study identified at least three different structural classes of compounds active against multidrug-resistant and extensively drug-resistant strains of tuberculosis. These new inhibitors target the reductive sulfur assimilation pathway, essential for the bacteria's survival in host defense systems.
Researchers at TSRI identify an enzyme that produces inflammatory lipid molecules in the brain, which causes a rare neurodegenerative disorder. The team finds a potential treatment approach by targeting this enzyme and discovers a weight-loss drug that can block its activity.
Researchers at Baylor College of Medicine discovered calcein inhibits TopBP1 activities, leading to anti-tumor effects. The study found calcein has potential as a treatment for multiple cancers, including breast and ovarian cancer.
Scientists identified a compound that effectively inhibits an enzyme crucial to Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) viruses. The compound has a different mode of action for each virus due to slight differences in the enzyme.
Researchers at the University of Alberta have developed a compound that targets a specific enzyme overexpressed in certain cancers. The enzyme inhibitor shows promise in turning glioblastoma cancer stem cells into normal cells and stopping their growth.
Lignin breakthroughs provide a new approach integrating biology, chemistry and engineering to understand how plants make products and structures needed for growth and development. The research team developed models that predict how pathway enzymes affect lignin content and composition.
A recent review article suggests that hydrogen sulfide has multiple anti-aging pathways, including inhibiting free-radical reactions and activating SIRT1. It also shows promise in treating age-related diseases such as cardiovascular disease, Parkinson's disease, and cancer.
Researchers at Scripps Research Institute have discovered new selective inhibitors of diacylglycerol lipases (DAGL), enzymes involved in making 2-AG, a key cannabinoid. Early tests suggest these compounds may also reduce pro-inflammatory molecules linked to rheumatoid arthritis, potentially leading to new therapeutic approaches.
Researchers have discovered compounds in berry wines that inhibit enzymes responsible for carbohydrate absorption, which could lead to a tasty and effective treatment for diabetes. The drinks contain high levels of anthocyanins, which have been shown to reduce inflammation and may have positive effects on cognitive function.
Researchers identified two enzymes, t-PA and MMP-3, that promote injury severity following traumatic brain injury (TBI). Inhibiting these enzymes may protect the brain from TBI by blocking the activation of MMP-3, which causes damage. The study provides a promising therapeutic target for treating human TBI.
Researchers at Emory University School of Medicine have identified a new class of anti-inflammatory compounds that inhibit the Nox2 enzyme, which produces reactive oxygen species. This approach may be more effective than traditional antioxidants in treating conditions like stroke, heart failure, and neurodegenerative diseases.
Researchers have developed chemical compounds that selectively block the attachment of sugar molecules to cells, potentially leading to new treatments for chronic inflammation, autoimmune diseases, and cancer. The new tools can help scientists understand how glycans influence cell function and behavior.
Scientists at Scripps Research Institute have discovered the first chemical compounds that inhibit PRMT1, an enzyme linked to asthma, arthritis, and certain cancers. The new inhibitors were identified using a selective screening technique that targets a specific amino acid found on PRMT1.
Elih Velázquez-Delgado uses X-ray crystallography to discover how nature inactivates caspase-6, a disease-related enzyme. He finds that deleting three specific amino acids reverses the effect and opens a door for developing a drug.
A Phase 2 pilot study will test the efficacy and safety of InflammaGen Shok-Pak, an enzyme inhibitor that blocks autodigestion, a condition leading to multi-organ failure. The treatment has shown promising results in pre-clinical studies and ex-U.S. patient experiences.
Researchers at Yale University have developed a practical method to synthesize huperzine A, a natural enzyme inhibitor that has been used to treat Alzheimer's disease in China. The compound shows promise in combating the effects of chemical warfare agents and may offer improved therapeutic benefits compared to existing treatments.
Researchers from Scripps Research Institute identify a class of compounds that powerfully block serine hydrolase activity without affecting other enzymes. The discovery opens up new avenues for studying these enzymes and developing treatments for various diseases.
Ischemic retinopathy is characterized by uncontrolled blood vessel formation in the retina. Researchers found that inhibiting an enzyme can prevent this by restoring balance between 'good guy' and 'bad guy' growth factors.
Research shows that inhibiting MMP enzymes slows down dental filling deterioration, preventing bacteria entry and decay. Chlorhexidine use can rapidly inhibit MMP activity, offering a practical solution for improved dental care.
The TRANSCEND study found that telmisartan modestly reduced cardiovascular events and hospitalizations for heart-related issues in patients with vascular disease or high-risk diabetes. The drug also had a lower rate of permanent discontinuation due to hypotension, according to the randomized controlled trial.
Scientists develop novel strategy to inhibit ß-secretase enzyme in Alzheimer's disease by targeting cell membrane RAFTS. The approach demonstrates effective inhibition of amyloid peptide formation with concentrations as low as 100 nM.
A newly discovered enzyme inhibitor identified by researchers looking for pest controls may provide pain relief for arthritis and inflammatory diseases sufferers. The finding, hailed as the most important discovery in inflammation in over a decade, reduces side effects associated with painkillers like Vioxx.
Researchers found that a gene-regulating enzyme is targeted by certain monoamine oxidase inhibitors used to treat depression. These drugs, such as tranylcypromine, may also have anti-cancer activity due to their ability to inhibit the growth of cancer cells.
UC Davis researchers found that therapy-induced leukemia develops from the rearrangement of the MLL gene and factors that activate programmed cell death. The process may be preventable by completing apoptosis in cancer cells, offering a potential treatment avenue.
In Canada, delisting prescription drugs from public health insurance programs transfers costs to private citizens or private health insurance plans, generating cost-savings for governments. Deregulation may also benefit pharmacists by increasing over-the-counter sales and expanding their clinical role.
The IMAGINE study found that adding an ACE inhibitor within seven days of CABG surgery does not improve current optimal treatment for low-risk patients without a clear indication. The trial, led by Canadian and international researchers, aimed to investigate the benefits of early post-surgical intervention with quinapril.
Researchers at UT Southwestern Medical Center discovered a vicious cycle of protein formation involving alpha-synuclein, leading to fibril formation and further protein clumping. The study suggests that inhibiting the malicious form of an enzyme could potentially lead to new treatment avenues for Parkinson's disease.
Researchers at UCSD have identified a promising set of inhibitors that may overcome drawbacks of previous compounds. The new molecules are less likely to cause side effects, such as one being the food additive Maltol.
A Canadian Medical Association Journal study found that reference-based pricing in British Columbia led to a significant reduction in the number of patients prescribed certain ACE inhibitors. The experiment aimed to reduce healthcare costs by tying medication prices to patient need, but its effectiveness remains unclear.